The dopaminergic ventral tegmental-striatal circuit protection hypothesis proposes that MAPT-encoded tau protein dysfunction specifically compromises dopaminergic neurotransmission through disrupted axonal transport and synaptic vesicle dynamics. Under normal conditions, tau protein facilitates the transport of tyrosine hydroxylase, aromatic L-amino acid decarboxylase, and vesicular monoamine transporter 2 (VMAT2) along dopaminergic axons projecting from the ventral tegmental area to the nucleus accumbens and dorsal striatum. Hyperphosphorylated tau at critical residues (Ser202/Thr205, Ser396/Ser404) mediated by GSK-3β and CDK5 disrupts microtubule stability, leading to impaired anterograde transport of dopamine synthesis machinery and synaptic vesicles. This results in reduced dopamine production at synaptic terminals and compromised vesicular packaging. Dopaminergic neurons are particularly vulnerable due to their extensive axonal arborization spanning long distances and their high metabolic demands for dopamine synthesis and vesicular transport.
...Curated pathway from expert analysis
graph TD
A["MAPT gene<br/>expression"]
B["Tau protein<br/>production"]
C["Hyperphosphorylated<br/>tau accumulation"]
D["Locus coeruleus<br/>neurons"]
E["Microtubule<br/>destabilization"]
F["Axonal transport<br/>impairment"]
G["Norepinephrine<br/>release reduction"]
H["Hippocampal<br/>noradrenergic<br/>denervation"]
I["Synaptic plasticity<br/>dysfunction"]
J["Neuroinflammation<br/>activation"]
K["Cellular stress<br/>response failure"]
L["Hippocampal tau<br/>pathology spread"]
M["Memory and<br/>cognitive decline"]
N["Noradrenergic<br/>replacement therapy"]
O["Tau aggregation<br/>inhibitors"]
A -->|"transcription"| B
B -->|"pathological<br/>modification"| C
C -->|"selective<br/>vulnerability"| D
D -->|"tau toxicity"| E
E -->|"transport<br/>disruption"| F
F -->|"neurotransmitter<br/>depletion"| G
G -->|"circuit<br/>disconnection"| H
H -->|"loss of<br/>modulation"| I
H -->|"reduced<br/>anti-inflammatory"| J
H -->|"impaired<br/>neuroprotection"| K
I -->|"functional<br/>decline"| M
J -->|"tissue<br/>damage"| L
K -->|"vulnerability<br/>increase"| L
L -->|"progressive<br/>pathology"| M
N -->|"circuit<br/>restoration"| H
O -->|"tau<br/>reduction"| C
classDef normal fill:#4fc3f7,color:#0d0d1a
classDef therapeutic fill:#81c784,color:#0d0d1a
classDef pathology fill:#ef5350,color:#0d0d1a
classDef outcome fill:#ffd54f,color:#0d0d1a
classDef molecular fill:#ce93d8,color:#0d0d1a
class A,B,D,G molecular
class E,F,I,K normal
class C,H,J,L pathology
class M outcome
class N,O therapeuticNo linked papers recorded for this hypothesis yet.
Median TPM across 13 brain regions for MAPT from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for MAPT.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.